ストックスクリーナーアプリを入手
7.9399
2.29%
0.2899
Transcode Therapeutics Inc (RNAZ) 最新ニュース
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World
Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday - Defense World
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World
(RNAZ) Investment Report - news.stocktradersdaily.com
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan
TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PR Newswire
Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus
Offerings News Live Feed - Stock Titan
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com South Africa
Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com
TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com
TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus
TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com
TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan
TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN
For Dropbox Inc [DBX], Analyst sees a drop to $30. What next? - dbtnews.com
Direct Digital Holdings Inc [DRCT] is -44.37% lower this YTD. Is it still time to buy? - dbtnews.com
CN Energy Group Inc [CNEY] Is Currently 9.75 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Wall Street Analyst Upgrade Rush Street Interactive Inc [RSI]. What else is Wall St. saying - dbtnews.com
why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com
Glaukos Corporation [GKOS] Revenue clocked in at $383.48 million, down -44.28% YTD: What’s Next? - dbtnews.com
Republic Digital Acquisition Company [RDAGU] Stock trading around $10.15 per share: What’s Next? - dbtnews.com
Venture Global Inc [VG] stock Initiated by UBS analyst, price target now $14 - dbtnews.com
Hayward Holdings Inc [HAYW] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Market cap of Solaris Energy Infrastructure Inc [SEI] reaches 1.55B – now what? - dbtnews.com
why Astera Labs Inc [ALAB] is a Good Choice for Investors After New Price Target of $111.21 - dbtnews.com
IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - Yahoo Finance
TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - The Globe and Mail
TransCode Therapeutics (RNAZ) Advances Clinical Trial of TTX-MC1 - GuruFocus
TransCode's Cancer Drug Achieves Major Safety Milestone: 13 Patients Show No Toxicity in Latest Trial Data - Stock Titan
EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug - Yahoo Finance
Selling Your TransCode Therapeutics Inc (NASDAQ: RNAZ) Stock? Here’s What You Need To Know - Stocksregister
TransCode Therapeutics (RNAZ) Adjourns Special Meeting to May 2 - GuruFocus
TransCode Therapeutics Inc (RNAZ) can make a big difference with a little luck - Sete News
Does Arbe Robotics Ltd (ARBE) offer a good opportunity for investors? - Sete News
A Look at Murphy Oil Corp (MUR) Shares in the Recent Past Indicates Growth - Sete News
TransCode Therapeutics Inc (RNAZ) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
TransCode Therapeutics stock slides after announces to raise $10M securities offering - MSN
TransCode Therapeutics Inc (RNAZ) deserves closer scrutiny - uspostnews.com
Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreases By 59.2% - Defense World
(RNAZ) Trading Signals - news.stocktradersdaily.com
What’s The Deal With TransCode Therapeutics Inc (NASDAQ: RNAZ)? - Stocksregister
TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum - Stock Titan
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - Yahoo Finance
What is the investor’s view on TransCode Therapeutics Inc (RNAZ)? - uspostnews.com
HC Wainwright Issues Pessimistic Forecast for RNAZ Earnings - The AM Reporter
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy - NewsBreak: Local News & Alerts
HC Wainwright Cuts TransCode Therapeutics (NASDAQ:RNAZ) Price Target to $10.00 - Defense World
Research Analysts Offer Predictions for RNAZ Q1 Earnings - Defense World
Transcode Therapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Transcode Therapeutics stock hits 52-week low at $0.34 - Investing.com
An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split if Necessary - Yahoo Finance
TransCode Therapeutics Inc: Weathering Stock Market Storms with 8.59M Market Cap - investchronicle.com
Transcode Therapeutics, Inc. SEC 10-K Report - TradingView
3.85%
4.85%
大文字化:
|
ボリューム (24 時間):